Heart Failure, Heart Failure, Diastolic
Conditions
Keywords
Heart failure; atrial septostomy
Brief summary
This study aims to investigate the safety and efficacy of personalized atrial septostomy (PAS) with combined use of radiofrequency-ablation and balloon-dilation (CURB) in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Detailed description
Atrial septostomy is an important palliative therapy in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) . Though the safety of balloon atrial septostomy (BAS) is satisfactory, the incidence of spontaneous closure is higher, which limits the clinical utilization of this procedure. The device-implantation improves the long-term patency. However, the created fenestration is limited with fixed size and it is further complicated with the potential device-related complications. Radiofrequency catheter ablation (RFA) has the potential to cause irreversible damage around the rim of fenestration created with BAS, which might prevent the re-adhesion of the septal remnants. In addition, RFA on fossae ovalis might reduce the elastic recoil of local tissue and contribute to create larger inter-atrial fenestration with same BAS procedure. Therefore, the combined use of radiofrequency-ablation and balloon-dilation (CURB) might become a novel procedure to create a stable inter-atrial fenestration. In this study, the adult patients who have HFrEF and HFpEF refractory to medical therapy may be eligible for this study.
Interventions
PROCEDUREPersonalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation
After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
Sponsors
China National Center for Cardiovascular Diseases
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the levels of AOP and MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 12 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years; 2. Symptomatic heart failure in NYHA class III or IV ambulatory; 3. Optimal medical therapy of heart failure according to European Society of Cardiology (ESC) guidelines for last 6 months; 4. LVEF ≥ 45%; 5. Elevated left heart filling pressures: left ventricular end-diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) ≥ 18 mmHg at rest; 6. LVEDP or PCWP-Mean right atrial pressure (MRAP) ≥ 5 mmHg; 7. Systolic blood pressure ≥ 90 mmHg.
Exclusion criteria
1. Acute infection or sepsis; 2. Intra-cardiac mass, thrombus or vegetation; 3. Evidence of right heart failure (TAPSE \< 14 mm); 4. Pulmonary hypertension (PASP \> 60 mmHg); 5. Associated atrial septal defect or large patent foramen ovale with significant left to right shunt in rest; 6. TIA or stroke within the last 6 months; 7. Thromboembolic events within the last 6 months; 8. Hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy as cause of heart failure; 9. Valvular diseases requiring therapy according to current ESC guidelines; 10. Life expectancy \< 1 year for non-cardiovascular reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical change | 12 months | Distance in 6 minutes walk test |
| The size of created-fenestration | 12 months | The change of created-fenestration size evaluated with echocardiography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percent of subjects who experience major adverse cardiac and cerebrovascular events (MACCE) | 12 months | Peri-procedural, and 12 months MACCE and systemic embolic events in patients after CURB procedure. |
| Change of PAWP or MLAP at rest | 12 months | Pulmonary capillary wedge pressure (PCWP)/MLAP at rest evaluated with right heart catheterization |
| Change of cardiac remodeling | 12 months | The change in cardiac chamber and function evaluated with MSCT and CMR |
| Myocardial remodeling | 12 months | The myocardial molecular imaging evaluated with PET-CT |
Countries
China
Outcome results
None listed